245 related articles for article (PubMed ID: 20448478)
1. Novel therapeutic targets for axonal degeneration in multiple sclerosis.
Petratos S; Azari MF; Ozturk E; Papadopoulos R; Bernard CC
J Neuropathol Exp Neurol; 2010 Apr; 69(4):323-34. PubMed ID: 20448478
[TBL] [Abstract][Full Text] [Related]
2. [Neuronal injury in multiple sclerosis].
Correale J; Meli F; Ysrraelit C
Medicina (B Aires); 2006; 66(5):472-85. PubMed ID: 17137182
[TBL] [Abstract][Full Text] [Related]
3. Axon loss is responsible for chronic neurological deficit following inflammatory demyelination in the rat.
Papadopoulos D; Pham-Dinh D; Reynolds R
Exp Neurol; 2006 Feb; 197(2):373-85. PubMed ID: 16337942
[TBL] [Abstract][Full Text] [Related]
4. Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models.
Lassmann H
Exp Neurol; 2010 Sep; 225(1):2-8. PubMed ID: 19840788
[TBL] [Abstract][Full Text] [Related]
5. Axonal degeneration in multiple sclerosis: defining therapeutic targets by identifying the causes of pathology.
Lee JY; Biemond M; Petratos S
Neurodegener Dis Manag; 2015 Dec; 5(6):527-48. PubMed ID: 26619755
[TBL] [Abstract][Full Text] [Related]
6. Astrocyte-associated axonal damage in pre-onset stages of experimental autoimmune encephalomyelitis.
Wang D; Ayers MM; Catmull DV; Hazelwood LJ; Bernard CC; Orian JM
Glia; 2005 Aug; 51(3):235-40. PubMed ID: 15812814
[TBL] [Abstract][Full Text] [Related]
7. Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation.
Petratos S; Ozturk E; Azari MF; Kenny R; Lee JY; Magee KA; Harvey AR; McDonald C; Taghian K; Moussa L; Mun Aui P; Siatskas C; Litwak S; Fehlings MG; Strittmatter SM; Bernard CC
Brain; 2012 Jun; 135(Pt 6):1794-818. PubMed ID: 22544872
[TBL] [Abstract][Full Text] [Related]
8. Relationship of acute axonal damage, Wallerian degeneration, and clinical disability in multiple sclerosis.
Singh S; Dallenga T; Winkler A; Roemer S; Maruschak B; Siebert H; Brück W; Stadelmann C
J Neuroinflammation; 2017 Mar; 14(1):57. PubMed ID: 28302146
[TBL] [Abstract][Full Text] [Related]
9. Neurodegeneration in autoimmune CNS inflammation.
Herz J; Zipp F; Siffrin V
Exp Neurol; 2010 Sep; 225(1):9-17. PubMed ID: 19961850
[TBL] [Abstract][Full Text] [Related]
10. Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis.
Herrero-Herranz E; Pardo LA; Gold R; Linker RA
Neurobiol Dis; 2008 May; 30(2):162-73. PubMed ID: 18342527
[TBL] [Abstract][Full Text] [Related]
11. Macrophages and neurodegeneration.
Hendriks JJ; Teunissen CE; de Vries HE; Dijkstra CD
Brain Res Brain Res Rev; 2005 Apr; 48(2):185-95. PubMed ID: 15850657
[TBL] [Abstract][Full Text] [Related]
12. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease.
Bjartmar C; Wujek JR; Trapp BD
J Neurol Sci; 2003 Feb; 206(2):165-71. PubMed ID: 12559505
[TBL] [Abstract][Full Text] [Related]
13. Neurodegeneration in autoimmune demyelination: recent mechanistic insights reveal novel therapeutic targets.
Aktas O; Waiczies S; Zipp F
J Neuroimmunol; 2007 Mar; 184(1-2):17-26. PubMed ID: 17222462
[TBL] [Abstract][Full Text] [Related]
14. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate.
Aharoni R; Vainshtein A; Stock A; Eilam R; From R; Shinder V; Arnon R
J Autoimmun; 2011 Nov; 37(3):228-41. PubMed ID: 21752599
[TBL] [Abstract][Full Text] [Related]
15. Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis.
Gresle MM; Shaw G; Jarrott B; Alexandrou EN; Friedhuber A; Kilpatrick TJ; Butzkueven H
J Neurosci Res; 2008 Dec; 86(16):3548-55. PubMed ID: 18709652
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of axonal degeneration in EAE--lessons from CNTF and MHC I knockout mice.
Linker RA; Sendtner M; Gold R
J Neurol Sci; 2005 Jun; 233(1-2):167-72. PubMed ID: 15949503
[TBL] [Abstract][Full Text] [Related]
17. Axonal degeneration is an early pathological feature in autoimmune-mediated demyelination in mice.
Onuki M; Ayers MM; Bernard CC; Orian JM
Microsc Res Tech; 2001 Mar; 52(6):731-9. PubMed ID: 11276125
[TBL] [Abstract][Full Text] [Related]
18. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS.
Craner MJ; Damarjian TG; Liu S; Hains BC; Lo AC; Black JA; Newcombe J; Cuzner ML; Waxman SG
Glia; 2005 Jan; 49(2):220-9. PubMed ID: 15390090
[TBL] [Abstract][Full Text] [Related]
19. [Axonal damage and its significance for the concept of neurodegeneration in multiple sclerosis].
Recks MS; Bader J; Kaiser CC; Schroeter M; Fink GR; Addicks K; Kuerten S
Fortschr Neurol Psychiatr; 2011 Mar; 79(3):161-70. PubMed ID: 21394707
[TBL] [Abstract][Full Text] [Related]
20. Neuronal NF-κB ablation does not influence neuro-axonal degeneration in experimental autoimmune demyelination.
Lee DH; Kubera K; Rosenthal B; Kaltschmidt B; Kaltschmidt C; Gold R; Linker RA
J Neuroimmunol; 2012 May; 246(1-2):38-42. PubMed ID: 22475633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
